MENU
SLXN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Silexion Therapeutics (SLXN) Ownership - Who owns Silexion Therapeutics?
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
7.75M
P/E Ratio
N/A
Total Cash
6.15M
Projected Growth
N/A
Total Debt
3.48M
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
0.65
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
SLXN
Capitalization
7.75M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
6.15M
Total Cash/Share
0.65
Total Debt
3.48M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
2.59M
P/B Ratio
3.00
Cash Flow
N/A
Earnings
-1.93
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
3.22
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-16.96M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-282.60
Shares Held By Institutions
209K
Shares Outstanding - Current
9.46M
Total Liabilities
5.72M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-59.204
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information